On December 30, Gelonghui reported that Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary Fujian Berry Hekang Genetic Technologies Co., Ltd. (referred to as "Berry Hekang") has signed a partnership agreement with Shanghai Zhikai Asset Management Co., Ltd., Fuzhou Xintou Venture Capital Co., Ltd., Shanghai Runda Medical Technology Co., Ltd., and Shanghai Fukairuikang Enterprise Management Consulting Partnership (Limited Partnership) to jointly invest in establishing the Fuzhou Xintou Zhikai Ruikang Venture Capital Fund Partnership (Limited Partnership). The partnership aims to raise a total of 0.134 billion yuan, with the company acting as a limited partner contributing 26.8 million yuan, accounting for 20.00% of the total partnership contribution.
The partnership will directly or indirectly invest in projects in the medical health sector, focusing on emerging industries that align with Fuzhou's development strategy, particularly high-end medical instruments, biomedical, and biomedical services.